Navigation Links
Rectal Cancer Outcomes Best With Short-Course Radiation
Date:3/5/2009

Even with latest surgical techniques, therapy should come first, studies suggest

THURSDAY, March 5 (HealthDay News) -- For people with operable rectal cancer, the most effective treatment is a short course of radiation therapy followed by "high-quality surgery," according to a new study.

Surgery is the standard treatment for rectal cancer, but just removing the tumor leaves a risk of cancer recurrence in the same area, according to background information. Previous research has shown that radiotherapy and chemotherapy after surgery can reduce the risk of recurrence. However, radiotherapy is costly and can cause long-term complications such as impaired bowel function, incontinence and sexual dysfunction.

The study involved 1,350 rectal cancer patients in the United Kingdom, Canada, South Africa and New Zealand. Professor Robert Steele, of Ninewells Hospital in Dundee, Scotland, and his colleagues randomly assigned the participants to receive five daily treatments of radiotherapy followed by surgery, or to have surgery followed by 25 treatments of chemo-radiotherapy.

Three years after treatment, 4.4 percent of those who had received radiotherapy before surgery had a local recurrence of the cancer, compared with 10.6 percent of those who had received radiotherapy after surgery. The disease-free survival rate after three years was 77.5 percent for people who had received pre-surgery radiotherapy and 72 percent for those who had gotten post-surgery radiotherapy. There was no significant difference in overall survival -- 157 deaths in the pre-surgery radiotherapy group and 173 deaths in the post-surgery group.

The findings were published in this week's issue of The Lancet.

Another study in the same issue of the journal found that recent improvements in surgical techniques have improved rectal cancer patient outcomes. Professor Phil Quirke, of the University of Leeds, in the United Kingdom, and his colleagues assessed how circumferential resection margin and the plane of surgery (the amount of tissue removed around the tumor) affected cancer recurrence risk in 1,156 people.

Of that group, 128 (11 percent) had involvement of the circumferential resection margin -- the presence of a tumor within 1 millimeter of the circumferential margin, which is associated with a high risk of local recurrence and poor survival. The plane of surgery was good (mesorectal) in 604 patients (52 percent), intermediate (intramesorectal) in 398 (34 percent) and poor (muscularis propria plane) in 154 (13 percent).

Three years after surgery, cancer had recurred locally in 6 percent of those with a negative circumferential margin and in 17 percent who had a positive circumferential margin. Local recurrence occurred in 4 percent of people in the mesorectal group, 7 percent in the intramesorectal group and 13 percent in the muscularis propria plane group.

For any plane of surgery achieved, short-course radiotherapy before surgery reduced local recurrence by about half, the study found.

"At present, only 50 percent of rectal cancer surgery is done in the mesorectal plane, suggesting that a further decrease in local recurrence rates might be obtained by improving the plane of surgery achieved," the researchers concluded. "[This could] be achieved through education and surgical tuition."

The findings of these studies show that "perioperative radiation can mitigate but not eliminate the adverse effects of imperfect surgery," Dr. Robert Madoff, of the University of Minnesota, wrote in an accompanying comment in the journal. "The best outcomes occurred when preoperative radiation was followed by optimum surgery. … The next challenge is to understand which patient needs what therapy to maximize his or her chances for a cure."

More information

The American Cancer Society has more about colorectal cancer.



-- Robert Preidt



SOURCE: The Lancet, news release, March 6, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. American College of Gastroenterology Issues Updated Colorectal Cancer Guidelines
2. No differences in survival or neonatal outcomes in pregnancy-associated colorectal cancer
3. Economy could reduce colorectal cancer screening rate
4. Gaps in colorectal cancer screening persist between whites and non-whites
5. Biomarker predicts disease recurrence in colorectal cancer
6. Long-Term Aspirin Use Seems to Protect Against Colorectal Lesions
7. Colorectal cancer: Immunological tests for more accurate detection of cancer precursors
8. Polymedco Introduces New Colorectal Cancer Educational Website
9. African-Americans have worse prognosis at colorectal cancer diagnosis
10. Hormone Therapy May Cut Colorectal Cancer Risk
11. Narrow-band imaging comparable to white light colonoscopy in differentiating colorectal polyps
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Rectal Cancer Outcomes Best With Short-Course Radiation
(Date:2/17/2017)... ... February 17, 2017 , ... For ... assistance management solution to the exhibit floor for the 2017 HIMSS Conference ... , From Feb. 19–23, 2017, more than 40,000 healthcare industry professionals are expected ...
(Date:2/17/2017)... Seattle, WA (PRWEB) , ... February 17, 2017 ... ... health management organizations, has been named a finalist in the 8th Annual DecisionHealth ... impacting America's healthcare delivery system. Qualis Health’s work is recognized across multiple award ...
(Date:2/17/2017)... ... 2017 , ... Pharmica Consulting attended CHI's 8th Annual SCOPE ... trial planning and management. Pharmica discussed the importance of effective project management, data ... by Pharmica’s booth were able to demo its cloud-based Resource Management Tool, ...
(Date:2/17/2017)... ... February 17, 2017 , ... Top neuroendocrine cancer doctors, nurses and specialists from ... February 21 - 23 in Beaver Creek, CO. It was announced today by Cindy ... year in Beaver Creek, hosting over 60 faculty members and addressing unmet needs of ...
(Date:2/16/2017)... ... 17, 2017 , ... For some cancer survivors, the memories ... Physician researchers at The Marcus Institute of Integrative Health at Thomas Jefferson ... reducing symptoms of traumatic stress in cancer patients and published their results ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... 17, 2017  Noble Capital Markets announced today that ... (Nasdaq: EPIX ). The report was issued ... , PhD. ESSA Pharmaceuticals is a clinical ... cancer (CRPC). Its lead compound EPI-506, is a small ... of the androgen receptor, thereby has potential to overcome ...
(Date:2/16/2017)... Quest Diagnostics (NYSE: DGX ), ... announced that it has been named one of the ... The annual survey designated Quest Diagnostics as ... Pharmacy and Other Services" industry to attain Most Admired ... attain the designation. This is the second consecutive year ...
(Date:2/16/2017)... Feb. 16, 2017  Aralez Pharmaceuticals Inc. (NASDAQ: ... company, today announced that executive management will participate in ... held February 22-23, 2017. Adrian Adams , Chief ... at 1:35 p.m. local time on Wednesday, February 22, ... for the event may be accessed from the Investors ...
Breaking Medicine Technology: